Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BE TOGETHER pediatric plaque psoriasis study
jRCT2041240092Active, not recruiting
- Sponsor
- UCB
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Randomised, double-blind trial in plaque psoriasis comparing Bimekizumab with Ustekinumab (2 arms). Primary endpoints: PASI90 response at Week 16 and IGA 0/1 response at Week 16. Started Jul 2025; status: active, not recruiting.
02
Drugs
bimekizumabustekinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCT2041240092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041240092.